Maligne Erkrankungen

Balke-Want H, Keerthi V, Del Carmen Arenas M, Chen Y, Malipatlolla M, Klysz DD, Xu P, Ho K, Asano K, Stahl D, Huang J, Retherford A, Patel S, Fowler C, Maas L, Gkitsas-Long N, Jiang Q, Liu X, Ullrich R, George J, Heitzeneder S, Tunuguntla R, Sage J, Sotillo E, Mackall CL, Feldman SA. c-JUN enhances CRISPR knockin anti-B7-H3 CAR T cell function in small cell lung cancer and thoracic SMARCA4-deficient undifferentiated tumors. Cell Rep Med. 2026 Jan 20;7(1):102549. doi: 10.1016/j.xcrm.2025.102549.PMID: 41564857 

Balke-Want H, Gödel P, Schmid C, Ayuk FA, Friedrichs B, van Heteren P, Holtkamp S, Zadoyan G, Brillant C, Costa J, Hanssens L, Holzer T, Wöhle C, Biedermann S, Bürger I, Orentas RJ, Overstijns T, Scheid C, Holtick U, Miltenyi S, Hallek MJ, Borchmann P, Kutsch N. Zamtocabtagene Autoleucel in Relapsed/refractory B-NHL: 5-year Follow Up of a CD20/19 tandem CAR T Cell Phase 1 Trial. Blood Adv. 2026 Jan 9:bloodadvances.2025018073. doi: 10.1182/bloodadvances.2025018073. PMID: 41512222

Stahl D, Gödel P, Balke-Want H, Gholamipoorfard R, Segbers P, Tetenborg L, Koker M, Dörr J, Gregor L, Bachurski D, Rose F, Simon AG, Good Z, Jakob J, Häupl B, Nill M, Flümann R, Riet T, Lange D, Blakemore SJ, Baurmann H, Voltin CA, Potter N, Schlözer L, Freihammer M, Wagener-Ryczek S, Iuga AI, Heger JM, Ludwig H, Schleifenbaum JK, Propp J, Bröckelmann PJ, Jachimowicz RD, Knittel G, Borchmann S, Merkelbach-Bruse S, Pallasch C, Peifer M, Rybniker J, Quaas A, Nitz M, Brägelmann J, Müller W, Persigehl T, Bozek K, Theobald SJ, Büttner R, Oellerich T, Hallek M, Kobold S, Chmielewski M, Reinhardt HC, Mackall C, Abedpour N, Borchmann P, Ullrich RT. CSF1R⁺ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma. Cancer Cell. 2025 Aug 11;43(8):1476-1494.e10. doi: 10.1016/j.ccell.2025.05.013. Epub 2025 Jun 12. PMID: 40513575.

Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, Jäger U, Cartron G, Izutsu K, Dreyling M, Kahl B, Ghesquieres H, Ardeshna K, Goto H, Barbui AM, Abramson JS, Borchmann P, Fleury I, Mielke S, Skarbnik A, de Vos S, Kamdar M, Karmali R, Viardot A, Farazi T, Fasan O, Lymp J, Vedal M, Nishii R, Avilion A, Papuga J, Kumar J, Nastoupil LJ. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat Med. 2024 Aug;30(8):2199-2207. doi: 10.1038/s41591-024-02986-9. Epub 2024 Jun 3. Erratum in: Nat Med. 2024 Aug;30(8):2374. doi: 10.1038/s41591-024-03175-4. PMID: 38830991; PMCID: PMC11333271.

Voltin CA, Paccagnella A, Winkelmann M, Heger JM, Casadei B, Beckmann L, Herrmann K, Dekorsy FJ, Kutsch N, Borchmann P, Fanti S, Kunz WG, Subklewe M, Kobe C, Zinzani PL, Stelljes M, Roth KS, Drzezga A, Noppeney R, Rahbar K, Reinhardt HC, von Tresckow B, Seifert R, Albring JC, Blumenberg V, Farolfi A, Flossdorf S, Gödel P, Hanoun C. Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy. Eur J Nucl Med Mol Imaging. 2024 Apr;51(5):1361-1370. doi: 10.1007/s00259-023-06554-0. Epub 2023 Dec 20. PMID: 38114616; PMCID: PMC10957657.

Prinz LF, Riet T, Neureuther DF, Lennartz S, Chrobok D, Hübbe H, Uhl G, Riet N, Hofmann P, Hösel M, Simon AG, Tetenborg L, Segbers P, Shimono J, Gödel P, Balke-Want H, Flümann R, Knittel G, Reinhardt HC, Scheid C, Büttner R, Chapuy B, Ullrich RT, Hallek M, Chmielewski MM. An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL. Cell Rep Med. 2024 Feb 20;5(2):101421. doi: 10.1016/j.xcrm.2024.101421. Epub 2024 Feb 9. PMID: 38340727; PMCID: PMC10897622.

Mackensen A, Haanen JBAG, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, Heudobler D, Ferstl B, Klobuch S, Bokemeyer C, Desuki A, Lüke F, Kutsch N, Müller F, Smit E, Hillemanns P, Karagiannis P, Wiegert E, He Y, Ho T, Kang-Fortner Q, Schlitter AM, Schulz-Eying C, Finlayson A, Flemmig C, Kühlcke K, Preußner L, Rengstl B, Türeci Ö, Şahin U. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023 Nov;29(11):2844-2853. doi: 10.1038/s41591-023-02612-0. Epub 2023 Oct 23. PMID: 37872225; PMCID: PMC10667102.

Fan J, Adams A, Sieg N, Heger JM, Gödel P, Kutsch N, Kaul D, Teichert M, von Tresckow B, Bücklein V, Goesmann G, Li M, Struve N, Trommer M, Linde P, Rosenbrock J, Celik E, Penack O, Stuschke M, Subklewe M, Belka C, von Bergwelt-Baildon M, Borchmann P, Marnitz S, Baues C. Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy. Radiother Oncol. 2023 Jun;183:109580. doi: 10.1016/j.radonc.2023.109580. Epub 2023 Feb 25. PMID: 36842663.

Voltin CA, Gödel P, Beckmann L, Heger JM, Kobe C, Kutsch N, Borchmann P, Dietlein M, Herrmann K, Stelljes M, Rahbar K, Lenz G, Reinhardt HC, Teichert M, Noppeney R, Albring JC, Seifert R, von Tresckow B, Flossdorf S, Hanoun C. Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy. Hemasphere. 2023 Jan 6;7(1):e817. doi: 10.1097/HS9.0000000000000817. PMID: 36698613; PMCID: PMC9829285.

Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021 Oct;22(10):1403-1415. doi: 10.1016/S1470-2045(21)00375-2. Epub 2021 Sep 10. PMID: 34516954.

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1. PMID: 30501490.